← Back to Search

Virtual Reality Therapy for Stroke Recovery

N/A
Recruiting
Led By Anouk Lamontagne, PhD
Research Sponsored by McGill University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
People with chronic stroke and persistent deficits in walking / visual-perceptual / cognitive capacities
Ability to walk independently with/without walking aids for at least 1 min at 0.4-0.9 m/s
Must not have
Subjects with comorbidities interfering with walking
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (week0), pre-intervention (week4), post-intervention (week8) and follow-up (week12)
Awards & highlights
No Placebo-Only Group

Summary

This trial will test a new VR rehabilitation intervention to help stroke survivors ambulate better in their community. The study will assess feasibility, safety, and efficacy of the intervention.

Who is the study for?
This trial is for chronic stroke survivors aged 40-74 with walking, cognitive, or visual-perceptual deficits. They must have had their first-ever unilateral stroke 9-24 months prior and be able to walk independently at a certain speed. Participants need normal vision/hearing (with aids if necessary) and mild-to-moderate hemiparesis.
What is being tested?
The study tests a new intervention combining virtual reality (VR) and field training aimed at improving community walking skills in stroke survivors. It involves VR exercises in a simulated environment and supervised outdoor walking practice over a four-week program.
What are the potential side effects?
Potential side effects may include discomfort from wearing VR goggles, motion sickness from the virtual environment, fatigue due to intensive training, or stress on affected limbs during ambulation practice.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have long-term effects from a stroke affecting my walking, vision, or thinking.
Select...
I can walk on my own with or without help for at least 1 minute.
Select...
I have some weakness on one side of my body but can still move.
Select...
I am between 40 and 74 years old.
Select...
My vision and hearing are normal or corrected to normal.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have health conditions that make it hard for me to walk.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (week0), pre-intervention (week4), post-intervention (week8) and follow-up (week12)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (week0), pre-intervention (week4), post-intervention (week8) and follow-up (week12) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in the Six Minute Walk Test (6MWT) at Follow-up
Post-intervention change in the Six Minute Walk Test (6MWT)
Secondary study objectives
5m Walk Test
Activities-Specific Balance Confidence Scale
Assessment of Life Habits (Life-H: mobility and community life domains)
+3 more
Other study objectives
Acceptability of the intervention
Adherence to intervention
Cadence
+5 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Virtual Reality and Field Practice Training (VRFT)Experimental Treatment1 Intervention
Participants will engage in a 4-week VRFT intervention that comprises of 1-hour training sessions, 3 times/week.

Find a Location

Who is running the clinical trial?

Jewish Rehabilitation HospitalOTHER
6 Previous Clinical Trials
770 Total Patients Enrolled
3 Trials studying Stroke
200 Patients Enrolled for Stroke
Laval UniversityOTHER
431 Previous Clinical Trials
178,397 Total Patients Enrolled
4 Trials studying Stroke
1,915 Patients Enrolled for Stroke
Integrated University Health and Social Services Center of the Capitale-NationaleOTHER
4 Previous Clinical Trials
543 Total Patients Enrolled
~5 spots leftby May 2025